CA3047397A1 - Compositions and methods for inhibiting seizures - Google Patents

Compositions and methods for inhibiting seizures Download PDF

Info

Publication number
CA3047397A1
CA3047397A1 CA3047397A CA3047397A CA3047397A1 CA 3047397 A1 CA3047397 A1 CA 3047397A1 CA 3047397 A CA3047397 A CA 3047397A CA 3047397 A CA3047397 A CA 3047397A CA 3047397 A1 CA3047397 A1 CA 3047397A1
Authority
CA
Canada
Prior art keywords
composition
bacteria
subject
parabacteroides
diet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3047397A
Other languages
English (en)
French (fr)
Inventor
Elaine Hsiao
Jessica Yano
Helen VUONG
Christine OLSON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California, San Diego
Original Assignee
University of California, San Diego
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, San Diego filed Critical University of California, San Diego
Publication of CA3047397A1 publication Critical patent/CA3047397A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0216—Bacteriodetes, e.g. Bacteroides, Ornithobacter, Porphyromonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Dairy Products (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
CA3047397A 2016-12-20 2017-12-20 Compositions and methods for inhibiting seizures Pending CA3047397A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662436711P 2016-12-20 2016-12-20
US62/436,711 2016-12-20
US201762447992P 2017-01-19 2017-01-19
US62/447,992 2017-01-19
PCT/US2017/067548 WO2018119048A1 (en) 2016-12-20 2017-12-20 Compositions and methods for inhibiting seizures

Publications (1)

Publication Number Publication Date
CA3047397A1 true CA3047397A1 (en) 2018-06-28

Family

ID=62627881

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3047397A Pending CA3047397A1 (en) 2016-12-20 2017-12-20 Compositions and methods for inhibiting seizures

Country Status (7)

Country Link
US (3) US11129858B2 (cg-RX-API-DMAC10.html)
EP (1) EP3558329B1 (cg-RX-API-DMAC10.html)
JP (1) JP7166280B2 (cg-RX-API-DMAC10.html)
CN (2) CN119033822A (cg-RX-API-DMAC10.html)
AU (1) AU2017382197B2 (cg-RX-API-DMAC10.html)
CA (1) CA3047397A1 (cg-RX-API-DMAC10.html)
WO (1) WO2018119048A1 (cg-RX-API-DMAC10.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7166280B2 (ja) 2016-12-20 2022-11-07 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 発作を抑制する組成物及び方法
TWI767013B (zh) * 2017-06-14 2022-06-11 英商4D製藥研究有限公司 包含細菌品系之組成物
JP7520820B2 (ja) * 2018-09-20 2024-07-23 イェダ リサーチ アンド ディベロップメント カンパニー リミテッド 筋萎縮性側索硬化症の治療方法
CN113164527A (zh) * 2018-09-27 2021-07-23 芬奇治疗控股有限责任公司 用于治疗癫痫和相关障碍的组合物和方法
WO2020076043A1 (ko) * 2018-10-08 2020-04-16 한국생명공학연구원 우울증의 예방 또는 치료 효과를 가지는 장내 미생물 및 이의 용도
CN110227085A (zh) * 2019-07-16 2019-09-13 江苏省中医院 Akkermansia Muciniphila在制备抗抑郁药物或者保健品中的应用
EP4166149A4 (en) * 2020-06-12 2024-12-18 Morinaga Milk Industry Co., Ltd. COMPOSITION IMPROVING MITOCHONDRIAL FUNCTION
CN113367328B (zh) * 2021-06-11 2023-02-21 无锡市人民医院 一种调节肠道菌群和能量代谢的多阶段生酮饮食配方
WO2023001368A1 (en) * 2021-07-20 2023-01-26 Université Catholique de Louvain Prevention and/or treatment of reward dysregulation disorders
CA3226267A1 (en) * 2021-07-20 2023-01-26 Amandine EVERARD Prevention and/or treatment of reward dysregulation disorders
CN116370509A (zh) * 2023-02-27 2023-07-04 广州知易生物科技有限公司 嗜黏蛋白阿克曼氏菌在制备缓解和治疗癫痫的药物中的应用
WO2026096387A1 (en) * 2024-10-30 2026-05-07 Bloom Science, Inc. Probiotics and methods to reduce weight

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6461607B1 (en) 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
WO2014075745A1 (en) * 2012-11-19 2014-05-22 Université Catholique de Louvain Use of akkermansia for treating metabolic disorders
EP2958575B1 (en) * 2013-02-22 2019-04-03 The Regents of The University of California Composition comprising lactobaccilus johnsonii 456 and its use in treating or preventing diseases
KR101445243B1 (ko) * 2014-03-28 2014-09-29 서울대학교산학협력단 장내 세균의 군집과 기능의 변화를 이용한 대사성 및 염증성 질환의 조기진단
MA41020A (fr) * 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
EP3297727A1 (en) * 2015-05-21 2018-03-28 Yeda Research and Development Co. Ltd Bacterial populations for promoting health
CN114366759A (zh) * 2015-05-22 2022-04-19 亚利桑那大学董事会 用于治疗自闭症谱系障碍及相关症状的方法
JP7166280B2 (ja) 2016-12-20 2022-11-07 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 発作を抑制する組成物及び方法
US20220184084A1 (en) 2019-03-18 2022-06-16 The Regents Of The University Of California Compositions and methods for treating cushing's disease

Also Published As

Publication number Publication date
US11883441B2 (en) 2024-01-30
AU2017382197B2 (en) 2022-12-01
EP3558329B1 (en) 2024-01-31
US20240238350A1 (en) 2024-07-18
US11129858B2 (en) 2021-09-28
US20220184144A1 (en) 2022-06-16
US20200384037A1 (en) 2020-12-10
JP2020502281A (ja) 2020-01-23
AU2017382197A1 (en) 2019-07-04
JP7166280B2 (ja) 2022-11-07
CN119033822A (zh) 2024-11-29
EP3558329A4 (en) 2020-07-22
CN110325196B (zh) 2024-08-27
EP3558329A1 (en) 2019-10-30
CN110325196A (zh) 2019-10-11
US12364717B2 (en) 2025-07-22
EP3558329C0 (en) 2024-01-31
WO2018119048A1 (en) 2018-06-28

Similar Documents

Publication Publication Date Title
US12364717B2 (en) Compositions and methods for inhibiting seizures
US12292445B2 (en) Methods of selecting subjects for treatment with metabolomic modulators
TWI812624B (zh) 包含細菌品系之組成物
JP7798785B2 (ja) 代謝の健康を改善するための細菌株を含む組成物
JP2018513196A (ja) マイクロバイオーム制御因子及び関連するその使用
EP3965820A1 (en) Compositions and methods for promoting healthy neural development in an unborn baby
US20220265733A1 (en) Compositions comprising bacterial strains
BR112019026477A2 (pt) composições compreendendo cepas bacterianas
CN111263590A (zh) 具有体力提高作用及抗疲劳作用中的一种以上作用的组合物
WO2025038777A2 (en) Probiotics and methods to reduce appetite
WO2025189253A1 (en) Microbiota compositions and methods for treating disorders
US20220218762A1 (en) Compositions and methods for modulating cognitive behavior
US20250025516A1 (en) Compositions and methods for inhibiting seizures
Favaron et al. The ageing microbiome, pharmaceutical considerations, and therapeutic opportunities
EP4003381A1 (en) Compositions and methods for treating skin infections and other diseases
US20240293344A1 (en) Unsaturated Hydroxamic Acid Derivatives and Their Use for the Treatment and Prevention of an Ammonia-Associated Disease or Disorder
WO2026096387A1 (en) Probiotics and methods to reduce weight
WO2026044228A1 (en) Chorismate pathway metabolite compositions and methods of use thereof
US20250228909A1 (en) Therapeutic compositions and methods
CN118215491A (zh) 通过植物乳杆菌进行的谷氨酸盐消耗和gaba形成
NZ760637B2 (en) Compositions comprising bacterial strains

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220922

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241213

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241213

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241213

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250210

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250606

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250616

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250723

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250723

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251212

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251212

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260407

R00 Party data change recorded

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R00-R119 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUEST

Effective date: 20260609

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R00-R116 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUEST

Effective date: 20260609

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260610

R17 Change to representative recorded

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R17-R121 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260625

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R17-R117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260625

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260625

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20260731